Share on StockTwits

Brean Capital raised their target price on shares of TG Therapeutics (NASDAQ:TGTX) from $13.00 to $19.00 in a research note issued on Tuesday. The firm currently has a “buy” rating on the stock. Brean Capital’s target price would indicate a potential upside of 130.16% from the company’s current price.

Shares of TG Therapeutics (NASDAQ:TGTX) traded down 13.92% during mid-day trading on Tuesday, hitting $8.255. The stock had a trading volume of 1,665,888 shares. TG Therapeutics has a 52-week low of $2.97 and a 52-week high of $11.56. The stock has a 50-day moving average of $9.02 and a 200-day moving average of $6.61. The company’s market cap is $309.4 million.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, July 22nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.08. On average, analysts predict that TG Therapeutics will post $-1.05 earnings per share for the current fiscal year.

A number of other firms have also recently commented on TGTX. Analysts at MLV & Co
raised their price target on shares of TG Therapeutics from $10.00 to $16.00 in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock. Separately, analysts at Ladenburg Thalmann set a $18.00 price target on shares of TG Therapeutics in a research note on Monday, June 16th. Finally, analysts at Roth Capital reiterated a “focus list” rating on shares of TG Therapeutics in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. TG Therapeutics has a consensus rating of “Buy” and a consensus target price of $16.74.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.